Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1371/journal.pone.0195945 http://scihub22266oqcxt.onion/10.1371/journal.pone.0195945 C5912777!5912777!29684049     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       PLoS+One 2018 ; 13 (4): ä Nephropedia Template TP {{tp|p=29684049|t=2018. Clinical factors associated with early progression and grade 3?4 toxicity in patients with advanced non-small-cell lung cancers treated with nivolumab |pdf=|usr=}}{{29684049}} gab.com Text Clinical factors associated with early progression and grade 3 4 toxicity in patients with advanced non-small-cell lung cancers treated with nivolumab JO: PLoS One http://www.kidney.de/pget.php?&tw=1&pmid=29684049 #FOAvip Introduction: The prognosis of advanced non-small-cell lung cancer (NSCLC) has been improved by development of immune checkpoint inhibitors (ICIs) such as nivolumab for second-line treatment. As phase III trials include only selected patients, we here investigated the clinical factors associated with efficacy and safety of nivolumab in ?real life? patients with advanced NSCLC. Methods: Clinical and histological characteristics, therapies and survival data of all consecutive patients with advanced NSCLC included prospectively and treated by nivolumab in two French academic hospitals between February 2015 and December 2016 were examined. Results: Sixty-seven patients were included, mostly male (69%), current or former smokers (87%) with PS <2 (73%). Median age was 68.5 years and 42% were aged ?70 years. According to uni- and multi-variate analyses, only PS 2 (OR = 0.17, 95% CI 0.03?0.99, p = 0.049) and number of previous treatment lines (OR = 0.33, 95% CI 0.13?0.85, p = 0.022) were significantly negatively associated with tumor control. Worse progression-free survival (PFS) was significantly associated with PS 2 (HR = 5.17, 95% CI 1.99?13.43, p = 0.001) and use of steroids (HR = 3.27, 95% CI 1.39?7.69, p = 0.006). Worse overall survival was associated with symptomatic brain metastasis (HR = 3.15, 95% CI 1.23?8.85, p = 0.029). Treatment-related adverse events occurred in 47 patients (70%), symptomatic brain metastasis being significantly associated with Grade ?3 toxicity (OR = 8.13, 95% CI 1.21?55.56, p = 0.031). Age and nutritional status were not associated with response, PFS, OS or toxicity. Conclusion: Our results suggest that nivolumab is not beneficial or safe for patients with PS 2 and symptomatic brain metastases. Twit Text FOAVip Clinical factors associated with early progression and grade 3 4 toxicity in patients with advanced non-small-cell lung cancers treated with nivolumab ????PLoS One http://www.kidney.de/pget.php?&tw=1&pmid=29684049 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=29684049 #FOAvip English Wikipedia <ref>{{Cite pmid|29684049}}</ref> Clinical factors associated with early progression and grade 3?4 toxicity in patients with advanced non-small-cell lung cancers treated with nivolumab #MMPMID29684049 Dumenil C; Massiani MA; Dumoulin J; Giraud V; Labrune S; Chinet T; Giroux Leprieur E PLoS One 2018[]; 13 (4): ä PMID29684049show ga Introduction: The prognosis of advanced non-small-cell lung cancer (NSCLC) has been improved by development of immune checkpoint inhibitors (ICIs) such as nivolumab for second-line treatment. As phase III trials include only selected patients, we here investigated the clinical factors associated with efficacy and safety of nivolumab in ?real life? patients with advanced NSCLC. Methods: Clinical and histological characteristics, therapies and survival data of all consecutive patients with advanced NSCLC included prospectively and treated by nivolumab in two French academic hospitals between February 2015 and December 2016 were examined. Results: Sixty-seven patients were included, mostly male (69%), current or former smokers (87%) with PS <2 (73%). Median age was 68.5 years and 42% were aged ?70 years. According to uni- and multi-variate analyses, only PS 2 (OR = 0.17, 95% CI 0.03?0.99, p = 0.049) and number of previous treatment lines (OR = 0.33, 95% CI 0.13?0.85, p = 0.022) were significantly negatively associated with tumor control. Worse progression-free survival (PFS) was significantly associated with PS 2 (HR = 5.17, 95% CI 1.99?13.43, p = 0.001) and use of steroids (HR = 3.27, 95% CI 1.39?7.69, p = 0.006). Worse overall survival was associated with symptomatic brain metastasis (HR = 3.15, 95% CI 1.23?8.85, p = 0.029). Treatment-related adverse events occurred in 47 patients (70%), symptomatic brain metastasis being significantly associated with Grade ?3 toxicity (OR = 8.13, 95% CI 1.21?55.56, p = 0.031). Age and nutritional status were not associated with response, PFS, OS or toxicity. Conclusion: Our results suggest that nivolumab is not beneficial or safe for patients with PS 2 and symptomatic brain metastases. äClinical factors associated with early progression and grade 3?4 toxic(epmc).pdf DeepDyve Pubget Overpricing